Founder & Senior Executive Vice Chairman of Sino Biopharmaceutical Picks Up 1.8% More Stock

Those following along with Sino Biopharmaceutical Limited (HKG:1177) will no doubt be intrigued by the recent purchase of shares by Ping Tse, Founder & Senior Executive Vice Chairman of the company, who spent a stonking HK$222m on stock at an average price of HK$7.44. While that only increased their holding size by 1.8%, it is still a big swing by our standards.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Sino Biopharmaceutical Insider Transactions Over The Last Year

Notably, that recent purchase by Ping Tse is the biggest insider purchase of Sino Biopharmaceutical shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$7.74. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Sino Biopharmaceutical share holders is that insiders were buying at near the current price. Notably Ping Tse was also the biggest seller.

In the last twelve months insiders purchased 31.87m shares for HK$236m. On the other hand they divested 13.80m shares, for HK$51m. In the last twelve months there was more buying than selling by Sino Biopharmaceutical insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

See our latest analysis for Sino Biopharmaceutical

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Sino Biopharmaceutical

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Sino Biopharmaceutical insiders own about HK$70b worth of shares (which is 51% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The Sino Biopharmaceutical Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Sino Biopharmaceutical. That's what I like to see! Of course, the future is what matters most. So if you are interested in Sino Biopharmaceutical, you should check out this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.